Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03597945
Other study ID # HS 1842015
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 30, 2015
Est. completion date April 29, 2018

Study information

Verified date June 2018
Source Faculty of Medicine, Sousse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prehospital management of traumatic pain is commonly based on morphine while loco-regional analgesia techniques, especially the femoral nerve block (FNB), can be safely and efficiently used. Adjuvants uses can reduce local anesthetic doses and decrease their related risk. The aim of the study was to assess the analgesic effect of Magnesium sulfate (Mg S) when used as adjuvant in prehospital FNB.

This is a randomized double-blinded trial conducted in a prehospital medical department of an academic hospital. Patients with isolated diaphysial femoral fracture and eligible to participate were randomized into 2 groups. The Group Placebo had a FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of normal saline. The Group Magnesium had a FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of Mg S 15% (450 mg). The FNB was performed according to the WINNIE technique. Primary endpoints were morphine consumption and pain intensity during the first 6 hours. Secondary end-points were the duration of the sensitive block, time to the first analgesic request, side effects occurrence.


Description:

After approval by the Research Ethics Board, this randomized double-blinded clinical trial was carried out in the prehospital medical department of a Tunisian teaching hospital over a 3 years period (April 30, 2015 to April 29, 2018). All patients with isolated diaphysial femoral fracture were enrolled. Inclusion criteria were age over 18 years, informed and writing consent.

Based on the results of a previous study and targeting a decrease of 1 cm in pain intensity assessed by the visual analogue score (VAS), the sample size was assessed to be at least 22 patients in each study group, considering a threshold of 0.05 and a study power of 90%. Sample size was increased in each group to 25 patients to allow possible dropouts.

Included patients randomly received, in a double-blind manner (using computer-generated allocation numbers sealed in brown envelopes), one of two local anesthetic solutions.

The control group (Group Placebo) had a FNB with 15 ml of lidocaine with epinephrine 0,005 mg/ml (300 mg) and 3 ml of normal saline.

The intervention group (Group Magnesium) had a FNB with 15 ml of lidocaine with epinephrine 0,005 mg/ml (300 mg) and 3 ml of Mg S 15% (450 mg).

FNB was performed according to WINNIE technique after rigorous asepsis. Its efficiency was evaluated 15 minutes after by pinprick test. Pain was assessed by visual analog scale (VAS) every 10 minutes for the first hour, then every 60 minutes until the 6th hour after the block. Patients with a VAS > 3 received morphine titration.

Primary endpoints were morphine consumption and pain intensity during the first 6 hours.

Secondary end-points were the duration of the sensitive block, time to the first analgesic request, the occurrence of side effects (erythematic, sedation, decrease in average blood pressure, or heart rate of more than 15% of the initial basic value).


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date April 29, 2018
Est. primary completion date April 29, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients with isolated diaphysial femoral fracture

- age over 18 years

- informed and writing consent

Exclusion Criteria:

- body mass index over 30

- fracture associated with vascular or sensory disorders

- cardiovascular diseases

- hepatic or renal impairments

- neuromuscular diseases

- opioids administration before the FNB

- chronic pain

- a long-term pain relief treatment

- pretreatment with calcium or calcium antagonist

- known allergy to one of the study drugs

- infection at the injection site

- open fracture

- fracture undocumented by the imagery

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
lidocaine with epinephrine
lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
normal saline
normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
Magnesium sulfate
Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Faculty of Medicine, Sousse

References & Publications (5)

Bondok RS, Abd El-Hady AM. Intra-articular magnesium is effective for postoperative analgesia in arthroscopic knee surgery. Br J Anaesth. 2006 Sep;97(3):389-92. Epub 2006 Jul 11. — View Citation

Capdevila X, Biboulet P, Bouregba M, Rubenovitch J, Jaber S. Bilateral continuous 3-in-1 nerve blockade for postoperative pain relief after bilateral femoral shaft surgery. J Clin Anesth. 1998 Nov;10(7):606-9. — View Citation

Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth. 1999 Aug;83(2):302-20. Review. — View Citation

Mukherjee K, Das A, Basunia SR, Dutta S, Mandal P, Mukherjee A. Evaluation of Magnesium as an adjuvant in Ropivacaine-induced supraclavicular brachial plexus block: A prospective, double-blinded randomized controlled study. J Res Pharm Pract. 2014 Oct;3(4 — View Citation

Schiferer A, Gore C, Gorove L, Lang T, Steinlechner B, Zimpfer M, Kober A. A randomized controlled trial of femoral nerve blockade administered preclinically for pain relief in femoral trauma. Anesth Analg. 2007 Dec;105(6):1852-4, table of contents. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary morphine consumption morphine requirements during the first 6 hours (mg) first 6 hours
Primary pain intensity: visual analog scale (VAS) pain intensity during the first 6 hours assessed by the visual analog scale (VAS) first 12 hours
Secondary sensitive block duration the duration of the sensitive block (in minutes) first 6 hours
Secondary time to the first analgesic request time to the first analgesic request in minutes first 6 hours
Secondary side effects occurrence the occurrence of side effects such as erythematic, sedation, decrease in average blood pressure, or heart rate of more than 15% of the initial basic value. first 12 hours
See also
  Status Clinical Trial Phase
Completed NCT03247179 - The Mobile PTSD Coach App in Acute Injury Survivors N/A
Completed NCT04133623 - Ibuprofen Versus Ketorolac by Mouth in the Treatment of Acute Pain From Osteoarticular Trauma Phase 3
Completed NCT05229965 - Paracetamol Vs Caffeine Vs Codeine in the Management of Post Traumatic Pain in Emergencies Phase 3
Completed NCT05630222 - Evaluation of Effect of Intravenous Morphine vs Intravenous Ibuprofen and Acetaminophen vs Intravenous Ibuprofen Phase 3
Recruiting NCT06351137 - Timecost of Intranasal Versus Intravenous Analgesia in Traumatic Pain N/A
Completed NCT03222518 - NSAIDs Versus Paracetamol Versus Paracetamol + NSAIDs in Traumatic Pain Management Phase 3
Completed NCT03256903 - Methoxyflurane vs Standard Analgesic Treatment for Trauma Pain in Spanish Emergency Units Phase 3
Completed NCT03080350 - Sublingual Versus Endovenous Fentanyl for the Prehospital Analgesia in Patients With Limb Trauma on the Slope Phase 4
Recruiting NCT06051227 - Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial Phase 3
Completed NCT04914988 - Continuous Fascia Iliaca Compartment Block in Geriatric Hip Fracture
Recruiting NCT03421275 - Intranasal Esketamine and Fentanyl for Pain in Minor Trauma Phase 4
Completed NCT03080324 - Sublingual Versus Endovenous Fentanyl for Pain Treatment in Trauma Patients in the Emergency Room Phase 4
Completed NCT01420159 - Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma Phase 3